Targeting inflammation in cardiovascular risk
The adverse effects of low-grade systemic inflammation are associated with the development of atherosclerosis, heart failure, obesity-related metabolic disorders, and chronic kidney disease. Because inflammation drives residual cardiovascular risk, Cardiometabolic Health Congress (CMHC) explores current and emerging anti-inflammatory agents in this setting. Inflammation in Atherosclerosis Atherosclerosis is no longer thought to be simply the result […]
Colchicine Administration in Patients with Chronic Coronary DiseaseÂ
Although the anti-inflammatory agent colchicine is currently approved to treat gout attacks and familial Mediterranean fever, when taken regularly in a long-term setting it may have other positive health effects. Research has shown that the compound may prevent conditions caused by inflammation, including several cardiometabolic diseases, however, evidence of its efficacy in risk reduction in patients […]
